Mitigative Effects of Topical Norfloxacin on an Imiquimod-Induced Murine Model of Psoriasis
ACS Pharmacology & Translational Science · 13.09.2024 · 7 (9) · 2739-2754
DOI: 10.1021/acsptsci.4c00152 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Pharmacology & Translational Science, online erschienen am 02.08.2024. Verfasst von Hayder Ridha-Salman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Pharmacy, Al-Mustaqbal University, Hillah 51001, Babylon +964, Iraq. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Al-Nahrain University.
Abstract (Originalsprache)
Psoriasis is a chronic, inflammatory dermatosis characterized by thickened, reddened, and scaly skin lesions. Norfloxacin is a fluoroquinolone antibiotic with enhanced antioxidant, anti-inflammatory, and immunomodulatory bioactivities. The aim of this study was to figure out the possible impact of topical norfloxacin on an imiquimod-induced model of psoriasis in mice. Thirty albino-type mice were split into five distinct groups of six animals each. The control group included healthy mice that had not received any treatment. The induction group was given the vehicle 2 h after the topical imiquimod, once daily for 8 days. Two hours after receiving topical imiquimod, the treatment groups including calcipotriol, norfloxacin 2.5%, and norfloxacin 5% were given topical ointments containing calcipotriol 0.005%, norfloxacin 2.5%, and norfloxacin 5%, for 8 days. Topical norfloxacin ointment significantly reduced the severity of imiquimod-exacerbated psoriatic lesions including erythema, shiny-white scaling, and acanthosis and fixed histological abnormalities. Furthermore, imiquimod-subjected mice treated with a higher concentration of norfloxacin ointment exhibited dramatically lower skin levels of inflammation-related biomarkers like IFN-γ, TNF-α, IL-6, IL-17A, IL-23, and TGF-β but higher levels of IL-10. They also demonstrated a notable decrease in angiogenesis parameters such as VEGF and IL-8, a substantial reduction in oxidative indicators like MDA and MPO, and a considerable rise in antioxidant enzymes like SOD and CAT. This study offers novel evidence that norfloxacin may assist in controlling inflammatory dermatoses like psoriasis by minimizing the severity of psoriatic plaques, correcting histological alterations, and diminishing the production of inflammatory, oxidative, and angiogenetic parameters.
Autor:innen und Institutionen
- Department of Pharmacology, College of Pharmacy, Al-Mustaqbal University, Hillah 51001, Babylon +964, Iraq.
- Department of Pharmacology, College of Pharmacy, Al-Esraa University, Baghdad +964, Iraq.
- Department of Pharmacology, College of Medicine, Al-Nahrain University, Baghdad +964, Iraq.
ORCID-Profile: Hayder Ridha-Salman
Förderung
- Al-Nahrain University
Zitieren
APA
Ridha-Salman, H., Shihab, E. M., Hasan, H. K., Abbas, A. H., Khorsheed, S. M., & Ayad Fakhri, S. (2024). Mitigative Effects of Topical Norfloxacin on an Imiquimod-Induced Murine Model of Psoriasis. ACS Pharmacology & Translational Science, 7(9), 2739-2754. https://doi.org/10.1021/acsptsci.4c00152
Vancouver
Ridha-Salman H, Shihab EM, Hasan HK, Abbas AH, Khorsheed SM, Ayad Fakhri S. Mitigative Effects of Topical Norfloxacin on an Imiquimod-Induced Murine Model of Psoriasis. ACS Pharmacology & Translational Science. 2024;7(9):2739-2754. doi:10.1021/acsptsci.4c00152
BibTeX
@article{RidhaSalman2024,
author = {Ridha-Salman, Hayder and Shihab, Elaf Mahmood and Hasan, Hasanain Kamil and Abbas, Alaa Hamza and Khorsheed, Shan Mohammed and Ayad Fakhri, Salar},
title = {Mitigative Effects of Topical Norfloxacin on an Imiquimod-Induced Murine Model of Psoriasis},
journal = {ACS Pharmacology & Translational Science},
year = {2024},
volume = {7},
number = {9},
pages = {2739--2754},
doi = {10.1021/acsptsci.4c00152}
}
EUVIMED